Get started
Award

CP20/00003

Funded outputs count: 21
Funder award ID: CP20/00003
OpenAlex ID: G2049349547
Fatty acid synthesis therapy-induced senescence (FASTIS) in cancer cells
2026 · Sara Verdura, Àngela Llop-Hernández, et al. · Cell Death and Disease
PDF
Mitochondrial bioenergetics-SASP crosstalk determines senolytic efficacy in therapy-induced senescence
2026 · Àngela Llop-Hernández, Sara Verdura, et al. · Cell Death Discovery · 2
PDF
Cellular Senescence in the Absence of Galactic Cosmic-Ray Muons
2026 · Àngela Llop-Hernández, Júlia López, et al. · Aging and Disease
PDF
Epigenetic Clocks in the Cosmic Silence of a Deep Underground Laboratory: Implications for Aging and Space Exploration
2026 · Javier A. Menendez, Carlos Peña-Garay, et al. · Aging and Disease
PDF
Mitochondrial priming in therapy-induced senescence: implications for CAR-T/NK immunosenolytic therapy
2025 · Javier A. Menendez, Ruth Lupu, et al. · Frontiers in Immunology · 4
PDF
Metabolic hallmarks of trastuzumab resistance
2025 · Begoña Martin-Castillo, Sara Verdura, et al. · Expert Opinion on Therapeutic Targets · 3
Fatty acid synthase (FASN) is a tumor-cell-intrinsic metabolic checkpoint restricting T-cell immunity
2024 · Elisabet Cuyàs, Stefano Pedarra, et al. · Cell Death Discovery · 33
PDF
Silibinin is a suppressor of the metastasis-promoting transcription factor ID3
2024 · Sara Verdura, José Antonio Encinar, et al. · Phytomedicine · 6
Fatty acid synthase ( FASN ) signalome: A molecular guide for precision oncology
2023 · Javier A. Menendez, Elisabet Cuyàs, et al. · Molecular Oncology · 31
PDF
Metabolomic and Mitochondrial Fingerprinting of the Epithelial-to-Mesenchymal Transition (EMT) in Non-Tumorigenic and Tumorigenic Human Breast Cells
2022 · Elisabet Cuyàs, Salvador Fernández-Arroyo, et al. · Cancers · 7
PDF
Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors
2022 · Sara Verdura, Jose Antonio Encinar, et al. · Cancers · 17
PDF
Circulating levels of MOTS-c in patients with breast cancer treated with metformin
2022 · Elisabet Cuyàs, METTEN study group, et al. · Aging · 5
PDF
Nutritional Niches of Cancer Therapy-Induced Senescent Cells
2022 · Àngela Llop-Hernández, Sara Verdura, et al. · Nutrients · 13
PDF
Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells
2022 · Sara Verdura, José Antonio Encinar, et al. · International Journal of Molecular Sciences · 9
PDF
Binding of the angiogenic/senescence inducer CCN1/CYR61 to integrin α6β1 drives endocrine resistance in breast cancer cells
2022 · Ingrid Espinoza, Lin Yang, et al. · Aging · 11
PDF
Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin
2021 · Joaquim Bosch-Barrera, Ariadna Roqué, et al. · Pharmaceuticals · 7
PDF
Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells
2021 · Barbara Schroeder, Travis Vander Steen, et al. · Cell Death and Disease · 97
PDF
Metformin Is a Pyridoxal-5′-phosphate (PLP)-Competitive Inhibitor of SHMT2
2021 · Angela Tramonti, Elisabet Cuyàs, et al. · Cancers · 33
Lung Cancer Management with Silibinin: A Historical and Translational Perspective
2021 · Sara Verdura, Elisabet Cuyàs, et al. · Pharmaceuticals · 58
PDF
Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer
2021 · Javier A. Menendez, Adriana Papadimitropoulou, et al. · Cancers · 41
PDF
Metformin: Targeting the Metabolo-Epigenetic Link in Cancer Biology
2021 · Elisabet Cuyàs, Sara Verdura, et al. · Frontiers in Oncology · 23
PDF
Year
Topic